Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SALVECO has developed and commercialized a unique patented lactic acid-based biocide technology ("Effibioz") that offers effective disinfection with a favorable safety and environmental profile. The products are validated under European regulations for simplified authorization due to their low-risk active ingredients. Clinical or preclinical results are not applicable as the products are intended for disinfection rather than direct therapeutic use in humans[1].
The company provides contract manufacturing and licensing of its technology to third-party brands.
Their approach enables the creation of tailor-made disinfectant formulas that minimize health and environmental risks while maintaining high efficacy against harmful microorganisms.
Products have been recognized by European regulatory authorities for their safety profile compared to traditional chemical biocides such as ADBAC or sodium hypochlorite[1].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SALVECO.